HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $100

Benzinga Newsdesk www.benzinga.com Positive 64.8%

Neg 0% Neu 0% Pos 64.8%

HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $80 to $100.